


# Rotherham Place Prescribing

**OCTOBER 2025**

 <https://mot.southyorkshire.icb.nhs.uk>

# Bitesize

## South Yorkshire CYP Asthma Guideline 2025.

South Yorkshire Children and Young People's Alliance are pleased to launch the new South Yorkshire CYP Asthma Guideline 2025.

The guideline can be found on the new South Yorkshire Medicines Optimisation Webpage here:  
[South Yorkshire Guideline South Yorkshire CYP asthma guideline 2025 V1.1.pdf](#)

This guideline details local recommendations for the management of asthma in children and young people aged 0-17. This guideline supersedes the existing CYP sections of local place-based guidance which are still available to access for adult guidance. An update to adult guidance will follow.

To support the launch of the guideline South Yorkshire CYP Alliance has hosted four webinars to introduce you to the new guidelines.

There will be a recorded version of this webinar available for those who have been unable to attend.

## Changes to the Selected List Scheme in Relation to Erectile Dysfunction (ED) Medications

From the 1<sup>st</sup> October 2025, tadalafil and vardenafil have been removed from the Selected List Scheme (SLS) in the Drug Tariff. This now means that these agents, along with sildenafil, can be considered as an option for treating ED in primary care without prescribing restrictions. Sildenafil remains the first choice of PDE5i but patients who do not tolerate sildenafil will now have a greater range of treatment options. It is recommended that patients try at least TWO PDE5is at maximal doses before being regarded as a non-responder.

## World AMR Awareness week 18<sup>th</sup>-24<sup>th</sup> November

Various webinars scheduled throughout the week on topics such as:

- Empowering Health Professionals in the Fight Against AMR
- A gut feeling the antibiotic use and antimicrobial resistance in children is a secondary consideration
- And more....

Sign up for the webinars here: [World Antimicrobial Resistance \(maAwareness Week - Antimicrobial Resistance Programme - Futures\)](#) (May require creating a free NHS Futures account first)

### MHRA summary:

- [Nitrofurantoin: reminder of the risks of pulmonary and hepatic adverse drug reactions - GOV.UK](#)
- Trodelvy: Update to SmPC and reminder of risk of serious side effects
- Valproate prescribing report published
- MHRA reassures the public that taking paracetamol during pregnancy remains safe
- MHRA investigating unlicensed Botox products

- New Commission launched to accelerate NHS use of AI
  - MHRA and partners unite to reaffirm prescription weight-loss medicine advertising rules
- To subscribe to monthly email alerts of MHRA safety Roundup scan the QR code:



## Oral semaglutide (Rybelsus®)-risk of medication error due to introduction of new formulation with increased bioavailability.

Novo Nordisk have announced that Rybelsus® tablets 3mg, 7mg and 14mg strengths will be replaced by 1.5mg, 4mg and 7mg strengths (see table below). This change is happening as the new reformulated tablet is more bioavailable. Patients will take the new formulation in exactly the same way as they currently do. The new formulations are not currently available to prescribe via clinical systems. Information from the manufacturer indicates that incorporation into the various clinical systems is likely to happen in stages.

Initial formulation (one oval tablet)	Bioequivalent	New formulation (one round tablet)
3 mg (starting dose)	=	1.5mg mg (starting dose)
7 mg (starting dose)	=	4 mg (starting dose)
14 mg (starting dose)	=	9 mg (starting dose)

The two formulations will temporarily co-exist on the market, which may cause mix-ups. This could result in overdosing, which increases the risk of gastrointestinal adverse events e.g. nausea, vomiting and diarrhoea.

### **Actions for general practice teams:**

- Patients currently taking Rybelsus® should be informed and advised about the change in formulation and dose when the new formulation is prescribed or dispensed. See the [Patient Transition Guide](#)
- Patients starting Rybelsus® treatment should be prescribed the new formulation and be suitably informed by the prescriber or pharmacist.
- Review prescribing in your practice. Consider reviewing whether Rybelsus® has been effective in lowering HbA1c and weight loss in line with NICE [NG28](#) i.e. has it reduced a patient's HbA1c by 11mmol/mol AND has the patient had a 3% weight loss in 6 months.

## SY IMOC Update-October 2025

### **Dydrogesterone tablets** (new formulation-brand name Nalvee®)

- for women with progesterone insufficiencies (treatment of dysmenorrhoea, endometriosis, irregular menstrual cycles and pre-menstrual syndrome),
- as hormone replacement therapy in combination with an estrogen for women with an intact uterus
- dysfunctional bleeding or secondary amenorrhoea (the drug may be used with an estrogen in the management of these conditions)

This product was classified as **GREEN** in the South Yorkshire Traffic Light System (SYTLS).

### **Atogepant and Rimegepant for the prevention of migraine**

Both these agents were agreed as **AMBER G** on the SYTLS. However, the current **RED** status for both drugs is to remain in place until the production of training material for primary care has been completed and disseminated. Any requests from secondary care to take over prescribing of these drugs should be referred back to the specialist.